Contraceptives, Oral

"Contraceptives, Oral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both.

Descriptor ID	D003276
MeSH Number(s)	D27.505.696.875.360.276.210 D27.505.954.705.360.276.210
Concept/Terms	Contraceptives, Oral Contraceptives, Oral Oral Contraceptives Oral Contraceptives, Phasic Oral Contraceptives, Phasic Contraceptives, Phasic Oral Phasic Oral Contraceptives Oral Contraceptives, Low-Dose Oral Contraceptives, Low-Dose Contraceptives, Low-Dose Oral Low-Dose Oral Contraceptives Oral Contraceptives, Low Dose

Below are MeSH descriptors whose meaning is more general than "Contraceptives, Oral".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Reproductive Control Agents [D27.505.696.875]
Contraceptive Agents [D27.505.696.875.360]
Contraceptive Agents, Female [D27.505.696.875.360.276]
Contraceptives, Oral [D27.505.696.875.360.276.210]
Therapeutic Uses [D27.505.954]
Reproductive Control Agents [D27.505.954.705]
Contraceptive Agents [D27.505.954.705.360]
Contraceptive Agents, Female [D27.505.954.705.360.276]
Contraceptives, Oral [D27.505.954.705.360.276.210]

Below are MeSH descriptors whose meaning is related to "Contraceptives, Oral".

Below are MeSH descriptors whose meaning is more specific than "Contraceptives, Oral".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Contraceptives, Oral" by people in this website by year, and whether "Contraceptives, Oral" was a major or minor topic of these publications.

Bar chart showing 19 publications over 12 distinct years, with a maximum of 4 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1997	2	1	3
1999	1	0	1
2002	0	2	2
2004	1	1	2
2005	0	1	1
2006	1	0	1
2008	1	0	1
2009	1	0	1
2010	0	1	1
2013	0	1	1
2016	3	1	4

Below are the most recent publications written about "Contraceptives, Oral" by people in Profiles.

Samson ME, Adams SA, Mulatya CM, Zhang J, Bennett CL, Hebert J, Steck SE. Types of oral contraceptives and breast cancer survival among women enrolled in Medicaid: A competing-risk model. Maturitas. 2017 Jan; 95:42-49.

View in: PubMed
Moorman PG, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Peters ES, Schwartz AG, Terry P, Crankshaw S, Wang F, Schildkraut JM. Reproductive factors and ovarian cancer risk in African-American women. Ann Epidemiol. 2016 09; 26(9):654-62.

View in: PubMed
Samson ME, Adams SA, Merchant AT, Maxwell WD, Zhang J, Bennett CL, Hebert JR. Cardiovascular disease incidence among females in South Carolina by type of oral contraceptives, 2000-2013: a retrospective cohort study. Arch Gynecol Obstet. 2016 11; 294(5):991-997.

View in: PubMed
Banerjee C. Obesity, Oral Contraceptive Use, and Cerebral Venous Thrombosis in Women. JAMA Neurol. 2016 05 01; 73(5):512-3.

View in: PubMed
Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL, Hofmann JN, Chow WH, Purdue MP. Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010. Am J Epidemiol. 2013 Jun 15; 177(12):1368-77.

View in: PubMed
Dempsey AR, Johnson SS, Westhoff CL. Predicting oral contraceptive continuation using the transtheoretical model of health behavior change. Perspect Sex Reprod Health. 2011 Mar; 43(1):23-9.

View in: PubMed
Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, Lynch CF, Bertelsen L, Capanu M, Concannon P, Borg A, Børresen-Dale AL, Diep A, Teraoka S, Torngren T, Xue S, Bernstein JL. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat. 2010 Feb; 120(1):175-83.

View in: PubMed
Figueiredo JC, Bernstein L, Capanu M, Malone KE, Lynch CF, Anton-Culver H, Stovall M, Bertelsen L, Haile RW, Bernstein JL. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group. J Clin Oncol. 2008 Mar 20; 26(9):1411-8.

View in: PubMed
Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1863-70.

View in: PubMed
Friedman LC, Kramer RM. Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr. 2005; (34):83-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals